A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2) - ScienceDirect
5
$ 12.99
In stock
(115)
Product Description
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial - ScienceDirect
Spotlight on Emerging Agents for Myeloproliferative Neoplasms - ppt download
PDF] Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice
Efficacy Results, Myelofibrosis Clinical Trials
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis - ScienceDirect
Effect sizes for changes from baseline in MFSAF total symptom score and
A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2) - ScienceDirect
The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis - ScienceDirect
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study - The Lancet Haematology
Novel therapeutics in myeloproliferative neoplasms, Journal of Hematology & Oncology
